Announced Date: 2024-01-09 (January 09, 2024)
Buyer: GSK plc (GSK)
Seller: Aiolos Bio, Inc. (Aiolos)
Key Asset: AIO-001 (SHR-1905 from Hengrui)
.
Asset Modality: Monoclonal antibody
Asset Target: thymic stromal lymphopoietin (TSLP)
Potential Indication: asthma, potential additional indications including chronic rhinosinusitis with nasal polyps.
Current Stage: phase II-ready
.
Transaction and Payment Detail:
GSK will acquire Aiolos, Share holder of Aiolos Bio will be eligible to receive:
Upfront payment of $1 billion,
Certain success-based regulatory milestone payments up to $400 million.
Total up to $1.4 billion.
.
In addition, GSK will also be responsible for success-based milestone payments as well as tiered royalties owed to Hengrui.
.
Link:
